advanced melanomamelanomaMelanoma-intrinsicnivolumabUniversity of California IrvineipilimumabChao Family Comprehensive Cancer CenterPD-1 blockadeNSF-GRFP fellowshipPD-1 immunotherapy+3 more
…tors. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11–22.Geels SN, Moshensky A, Sousa R…